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Tissue factor (TF) is a transmembrane glycoprotein which, in association with factor VII(a), is the main activator of coagulation. In illnesses uch 
as Gram-negative ndotoxemia, circulating monocytes ynthesize and express ubstantial TF activity, resulting in extensive disseminated intravas- 
cular coagulation. We investigated the way in which TF is suppressed by pentoxifylline (PTX), and found that PTX down-regulates immunologic 
TF expression and specific mRNA production in response to LPS. Since TF mRNA stability is not altered, this effect appears to take place at 
the transcriptional level. 
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1. INTRODUCTION 
LPS-activated monocytes synthesize and express on 
their surface tissue factor (TF), a membrane-bound 
glycoprotein that serves as the essential cofactor for 
factor VII(a) in the initiation of coagulation via factors 
IX and X [l]. Subsequent exposure of blood or plasma 
to TF-positive monocytes induces pericellular fibrin [2]. 
The role of TF in triggering endotoxin-induced issem- 
inated intravascular coagulation has been recently em- 
phasized [3,4], and molecules down-regulating its pro- 
duction would be useful therapeutic tools. 
without PTX, at 37°C under 5% CO2 for 14 h, in RPM1 1640 supple- 
mented as described in [6]. The supernatant was then discarded and 
cells were washed and stored for less than one week at -80°C until 
PCA measurement or RNA extraction. 
After thawing, the cells were lysed and TF procoagulant activity 
(PCA) was assayed as described in [6,7]. PCA was expressed as TF 
milhunits/106 monocytes. In some experiments, the percentage of TF- 
initiated PCA was determined by measuring residual PCA after incu- 
bating the cell lysate with 10 &ml of a pool of neutralizing TF- 
monoclonal antibodies (TF8-5G9, TF8-6B4, and TF9-9C3) gener- 
ously given by T.S. Edgington [8]. 
Pentoxifylline (PTX) is a methylxanthine deriva- 
tive [1-(5-oxo-hexyl)-3,7_dimethylxanthine] (Torental, 
Hoechst) which inhibits phosphodiesterase [5]. Re- 
cently, we reported that PTX inhibits the TF procoagu- 
lant activity developed by monocytes in vitro in re- 
sponse to endotoxin, apparently through an early in- 
crease in intracellular cyclic AMP levels [6]. 
Total RNA was extracted by the guanidinium-thiocyanate/cesium 
chloride method [7]. Filters were hybridized for 24 h at 42°C either 
subsequently to the labeled TF and /I actin cDNA probes or simulta- 
neously with the TF and G3PDH cDNA probes. The autoradiograms 
were scanned by laser densitometry using the Sebia Preference R 
apparatus to determine the relative levels of mRNA in treated and 
untreated monocytes. 
In this study, we investigated the mechanism regulat- 
ing the response of TF to PTX in vitro with respect o 
immunologic TF expression, mRNA levels and mRNA 
stability. 
cDNA probes were labeled with [u-“P]dCTP (3,000 Ci/mmol) by 
random hexamer primer extension using the Amersham Multiprime 
kit. The 641 bp TF cDNA probe kindly provided by T.S. Edgington 
[9] was excised from plasmid pUC8 with EcoRI. The 822 bp /I actin 
cDNA probe was excised from plasmid pGEM3 with EcoRI and 
HindIII; the latter is a murine probe which cross-reacts with human 
actin mRNA and was kindly provided by Dr. Alvarado (Institut 
Pasteur, Paris). The G3PDH probe was purchased from Clontech 
(Palo Alto, CA). 
2. MATERIALS AND METHODS 
Peripheral blood monocytes (75-95%) were isolated from the by- 
products of normal donor plateletpheresis by Ficoll-Hypaque gradient 
sedimentation and adherence to gelatin/fibronectin-coated Petri dishes 
[7]. Adherent cells were incubated with 1 &ml LPS and with or 
The binding of an anti-human TF murine monoclonal (IgG) anti- 
body (MoAM, Corvas, San Diego, CA) was assessed by flow cytom- 
etric analysis [7]. Monocytes were gated using anti-CD14-positive cells 
detected after incubation with a phycoerythrin-conjugated anti-CD14 
mouse monoclonal antibody (Immunotech, Luminy, France) [7]. 
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3. RESULTS AND DISCUSSION 
We confirmed here that PTX inhibits the generation 
of TF-procoagulant activity by LPS-exposed mon- 
ocytes, in a concentration-dependent manner, (Fig. 1). 
The PCA was identified as TF since more than 99% was 
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Fig. 1. PTX induced parallel, ~on~ntration-de~ndent inhibitions of 
LPS-induced PCA (A) and TF mRNA (B). Five fig of total RNA was 
analysed by Northern blotting. RNA was extracted from untreated 
monocytes, or from cells exposed for 4 h to 1 &ml LPS or to 
LPS + PTX at 50 to 500 ,uM. The membranes were hybridized to TF 
and actin probes. Monocyte PCA was determined in the same system 
(A); (mean rtr S.D.; n = 3). 
inhibited by a cocktail of monoclonal antibodies to 
human TF (data not shown). 
Quantitation by flow cytometric analysis with a spe- 
cific monoclonal antibody showed that TF protein ex- 
pression on the cell surface and TF functional activity 
was decreased by PTX treatment (Fig. 2). The median 
fluorescence level was 30 in the absence of stimulation, 
200 after LPS treatment and 69 in the presence of PTX 
at 500 PM (65% decrease). PCA measured in the same 
experiment decreased from 6,346 to 2,346 mu/lo6 mon- 
ocytes (63% decrease). This is notable since the exis- 
tence of TF pathway inhibitor (TFPI) mRNA [IO] in 
both resting and LPS-stimulated monocytes suggests 
that this inhibitor may play a role in the decrease in TF 
activity. In addition, TF activity may be influenced by 
membrane composition, including increased phosphati- 
dylserine content in the outer leaflet of the plasma mem- 
brane [ 1 I]. 
TF mRNA was not detectable in unstimulated mon- 
ocytes (Fig. 1). In contrast, exposure to 1 yg/ml LPS for 
4 h was associated with high TF mRNA levels. The 
addition of 50-500 PM PTX to mono~ytes during LPS 
stimulation was associated with a concentration-de- 
pendent decrease in TF mRNA (Fig. 1). This involved 
both the 3. l- and 2.3-kilobase species. No changes in /? 
actin mRNA content were observed in control or drug- 
treated cells. Similarly, TF mRNA levels in monocytes 
exposed to 1 puglml LPS for O-4 h were compared with 
and without PTX (500pM) pretreatment (Fig. 3). Upon 
LPS stimulation, TF mRNA increased progressively 
from 0 to 4 h (Fig. 3), as previously reported by Gregory 





Fig. 2. Down-regulation of LPS-induced TF antigen expression ana- 
lyzed by flow cytometry in monocytes treated with PTX. Monocytes 
were incubated in culture medium (RPMI) or treated with LPS (1 
pg/ml) alone or LPS + 500pM PTX (PTX). The dotted line shows the 
maximal fluorescence intensity obtained with cells incubated in culture 
medium alone. 
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Fig. 3. Kinetics of PTX inhibition of LPS-induced PCA (A) and TF 
mRNA (C) from 0 to 4 h. RNA was extracted from freshly isolated 
monocytes (not shown) after I,2 and 4 h incubation with 1 pg/ml LPS 
alone or LPS + 500 ,uM PTX. Autoradiograms were scanned by laser 
densitometry and values were calculated relative to the G3PDH con- 
trol (B). The kinetics of monocyte PCA was determined in the same 
system (A); (mean+ SD.; n = 3). 
modified at the first hour but was profoundly decreased 
at 2 and 4 h. The PCA of similarly treated monocytes 
was determined concomitantly. PCA increased progres- 
sively from 0 to 4 h after LPS stimulation alone (Fig. 
3); after the addition of PTX, it fell by about 50% at 2 
and 4 h. The kinetics of mRNA inhibition by PTX was 
similar to that observed for PCA inhibition. 
The rate of mRNA degradation is an important po- 
tential regulator of gene expression. The half-life of the 
TF mRNA, with or without PTX pretreatment, was 
about 3.25 h. The yield of total RNA decreased simi- 
larly in both conditions (Fig. 4). This indicates that PTX 
does not alter the half-life of TF mRNA and strongly 
suggests an effect of PTX at the transcriptional evel. 
PTX decreases tumor necrosis factor cx mRNA accu- 
mulation in LPS-activated monocytes [131 and prevents 
thrombomodulin mRNA suppression in tumor necrosis 
factor a-exposed endothelial cells [ 141. In both cases the 
effect of PTX may occur partly via an increase in intra- 
cellular CAMP levels. On the basis of our previous re- 
sults [6], a similar mechanism is likely to be involved in 
the inhibition of LPS-induced generation of TF by 
PTX. Here, we show that the functional and immuno- 
logical alterations of LPS-induced TF, as well as the TF 
mRNA suppression induced by PTX, present similar 
characteristics to those reported to be induced by phar- 
macological agents that elevate intracellular CAMP 
levels [7]. 
Despite the strong evidence favoring a CAMP-de- 
pendent mechanism of PTX action, other possibilities 
should also be considered. PTX induces structural de- 
fects in the neutrophil cytoskeleton [15] and we have 
reported the inhibitory effect of antimicrotubular 
agents on monocyte TF production [16]. Recently, PTX 
was reported to be a scavenger of hydroxyl radicals and 
to have protective effects against hydroxyl radical-in- 
duced damage [17]. Since the effect of such radicals has 
been suggested to be involved in the LPS-induced 
transactivation of nuclear factor-kB [18], this mecha- 
nism might also contribute to TF mRNA down-regula- 
tion by PTX. 
Since TF probably has a prominent role in the initia- 
tion of coagulation [ 191, the suppression of TF produc- 
tion by PTX likely contributes trongly to its antithrom- 
botic effect [20]. Indeed, PTX is beneficial in septic 
shock in several animal experimental models [21,22]. 
Fletcher et al., however, insisted on the fact that PTX 
treatment can improve or worsen survival from LPS 
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Fig. 4. Effect of PTX on the stability of LPS-induced TF mRNA. 
Monocytes were exposed to LPS for 2 h to induce TF mRNA. The 
addition of actinomycin D (10 @ml) was followed by the addition of 
100 ,uM PTX. Total RNA was harvested at the indicated times after 
the addition of actinomycin D and analyzed by Northern blotting (A). 
Autoradiograms were scanned by laser densitometry. The stability of 
the 2.3 kb TF mRNA species is shown (B): q LPS alone, n 
LPS + PTX. 
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